Recruiting
Phase 1

ZEN-3694 & Pembrolizumab

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05422794

Conditions

Anatomic Stage III Breast Cancer AJCC v8

Anatomic Stage IV Breast Cancer AJCC v8

Locally Advanced Triple-Negative Breast Carcinoma

Metastatic Triple-Negative Breast Carcinoma

Unresectable Triple-Negative Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BET Bromodomain Inhibitor ZEN-3694

Biopsy

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information